Contract Pharma2h
OliX, Lilly Enter Global Licensing Agreement for Cardiometabolic Indications
To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Hosted on MSN22h
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.